Statins Safety Signals: From Precautions to Proportionate Evidence-Based Labeling.

Authors

Médéa Locquet, Jonathan Douxfils, Patrizio Lancellotti, Jean-Michel Dogné

Published in

Clinical pharmacology and therapeutics. Jul 28, 2026. Epub Jul 28, 2026.

Abstract

The recent Cholesterol Treatment Trialists' Collaboration meta-analysis provides the most comprehensive randomized evidence to date regarding statin-associated adverse drug reactions, substantially narrowing the list of harms confidently attributable to statins. Beyond its clinical implications, the analysis highlights important challenges in pharmacovigilance and regulatory risk communication. Precautionary labeling based on low-certainty evidence may inadvertently amplify nocebo effects, reduce adherence to preventive therapies, and contribute to avoidable cardiovascular burden, particularly among vulnerable populations.

PMID:
42522052
Bibliographic data and abstract were imported from PubMed on 29 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.